[ad_1]
The Medicines and Healthcare Products Surveillance Agency (MHRA) said overlapping studies and in-depth data analysis had been conducted since June to reach a decision in record time.
“This does not mean that the corners have been cut, at all,” agency director June Raine said at a news conference. “Public safety will always be paramount.”
The UK became the first Western country on Wednesday to approve a COVID-19 vaccine for widespread use. Starting next week, she will be vaccinated against the most vulnerable groups in society.
The vaccine, developed by Pfizer and BioNTech, is one of several that the drug regulator should approve in the coming weeks after completing the data analysis.
According to Raine, the “rigorous evaluation” of the MHRA vaccine began in June, when preliminary results of the first trials of a vaccine developed by Pfizer and BioNTech became available.
“If you climb a mountain, you are preparing for it,” he said.
“We were at base camp on November 10. When we receive the final analysis [rezultatų]”We were ready for the finish line, which has brought us to this day,” said J. Raine.
British Health Secretary Matt Hancock previously said that the National Health Service (NHS) would start vaccinating 800,000 people from “early next week”. vaccine dose.
By the end of the year, that number will hit “millions,” he said.
The mass vaccination program will begin with nursing home residents and health and social workers in the forefront.
[ad_2]
